Trial Profile
A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/Day) for the Treatment of Primary Insomnia in Adult Outpatients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Vestipitant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-006345-72).
- 14 Oct 2009 New trial record